IRCT20200623047902N6 IRCT 2021-08-14 Zistdaru Danesh Company Bioequivalence study of erlotinib 150 mg Bioequivalence study of erlotinib150mg tablet, manufactured by Zistdaru Danesh co. (Erloxha) Versus Tarceva 150 in healthy volunteers 2021-09-06 anticipated 24 Complete https://irct.ir/trial/57816 interventional Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Crossover, Purpose: Treatment, Randomization description: People in the mentioned age group are invited to participate through the advertisement. People are then checked for health and healthy volunteers are identified. Each candidate is assigned a number from 1 to 24. The numbers are written on a plastic ball and poured into a container and mixed. The balls are then removed randomly from the container. The first 12 no.s are considered as (first sequence: Erloxha 150) and the second 12 no.s are considered as (second sequence: Tarceva 150 recipient). The volunteers don't have any information about taking the test drug or brand drug, Blinding description: This study is a single-blinded clinical trial (volunteers). Erloxha and Tarceva tablets are removed from their packaging by the executor and placed in similar and coded cans. Volunteers will not be informed about receiving the brand or test dosage form. Bioequivalence In this study, the disease is not examined. The subject of the study is the bioequivalence study of Erlotinib tablet 150 mg of test and reference in healthy volunteers.. Intervention 1: Intervention group: single dose, one oral tablet of Tarceva 150 mg (Erlotinib) manufactured by Roche, as reference product. Intervention 2: Intervention group: Single dose, one oral tablet of Erloxha 150 mg (Erlotinib) manufactured by Zistdaru Danesh as test product. No - There is not a plan to make this available Justification or reason for not sharing IPD is These data are as secure between researcher and related industries.